The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The company has operations in North America, Asia, and Europe,
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Subscribe To Our Newsletter & Stay Updated
